Skip to Content

Madeleine Duvic, M.D.

Present Title & Affiliation

Primary Appointment

Deputy Department Chair, Department of Dermatology, Division of Internal Medicine, UTMDACC, Houston, TX
Professor of Medicine and Dermatology (with tenure), Division of Internal Medicine, UTMDACC, Houston, TX
Blanche Bender Professorship in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, UTMDACC, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Division of Epidemiology, Human Genetics & Environmental Sciences, The University of Texas School of Public Health, Houston, TX
Professor of Medicine and Dermatology, The University of Texas Medical School at Houston (UTMSH), Houston, TX

Bio Statement

Madeleine Duvic, M.D., Professor of Internal Medicine and Dermatology, is Deputy Chairman of the Department of Dermatology at The University of Texas, MD Anderson Cancer Center in Houston, Texas. She received her medical degree from Duke University Medical School and completed an internship and residencies in internal medicine and dermatology, served as chief resident, and completed a fellowship in molecular biology and geriatrics. She is a former board member of the American Academy of Dermatology and recent vice president of the Society for Investigative Dermatology. She was elected to the ADA and is a founder and board member of the United States Consortium for Cutaneous Lymphomas. She serves on Medical and Scientific Boards of the National Alopecia Areata Foundation and Cutaneous Lymphoma Foundation and is the Principal Investigator of the Alopecia Areata Registry.

Dr. Duvic has been named consistently as one of America’s Top Doctors by Castle Connolly and Best Doctors in America for 12 consecutive years. She has authored over 420 peer-reviewed journal articles, two books, and has mentored numerous medical students, residents, fellows, and PhD students.

She has been Principal Investigator of numerous clinical trials and translational research studies of T-cell mediated diseases and malignancies, including T-cell lymphomas, melanoma, and skin cancer. Her work is focused on developing and improving therapy for cutaneous T-cell lymphoma.


Clinical Interests


-     Cutaneous lymphomas and Sezary syndrome

-     Skin cancer and melanoma

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1452
Houston, TX 77030
Phone: (713) 745-4615 Clinic (713) 792-6800
Fax: (713) 745-3597

Education & Training

Degree-Granting Education

1977 Duke University Medical School, Durham, NC, MD, Medicine
1973 Rice University, Houston, TX, BA, Biology

Postgraduate Training

8/1984-6/1985 Research Visiting Fellow, Molecular Genetics, Baylor College of Medicine, Houston, TX, Dr. Thomas Caskey
7/1982-7/1984 Postdoctoral Fellowship, Molecular Genetics & Geriatrics, Duke University, Durham, NC, Drs. Russell Kaufman and Sheldon Pinnell
1981-1982 Residency in Internal Medicine, Duke University, Durham, NC
1979 Chief Resident, Dermatology, Duke University, Durham, NC
1978-1980 Residency in Dermatology, Duke University, Durham, NC
1977-1978 Internship in Internal Medicine, Duke University, Durham, NC

Board Certifications

9/1982 American Board of Internal Medicine
6/1981 American Board of Dermatology

Honors and Awards

2001-present America's Top Doctors, Castle Connolly Medical Ltd.
1994-present Best Doctors in America

Selected Publications

Peer-Reviewed Original Research Articles

1. Oh CW, Ivan D, Curry J, Ellis R, Gerber H, Duvic M, Torres-Cabala C. A Case of Indeterminate Dendritic Cell Tumor Presenting with Leonine Facies. J Cutan Pathol. e-Pub 8/2015. PMID: 26272726.
2. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of Brentuximab Vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. e-Pub 8/2015. PMID: 26261247.
3. Litvinov IV, Tetzlaff MT, Rahme E, Jennings MA, Risser DR, Gangar P, Netchiporouk E, Moreau L, Prieto VG, Sasseville D, Duvic M. Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med. e-Pub 7/2015. PMID: 26136403.
4. Ni X, Langridge T, Duvic M. Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. Oncoimmunology 4(7):e1011524, 7/2015. e-Pub 3/2015. PMCID: PMC4485778.
5. Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A, Redler S, Becker T, Heilmann S, Yamany T, Duvic M, Hordinsky M, Norris D, Price VH, Mackay-Wiggan J, de Jong A, DeStefano GM, Moebus S, Böhm M, Blume-Peytavi U, Wolff H, Lutz G, Kruse R, Bian L, Amos CI, Lee A, Gregersen PK, Blaumeiser B, Altshuler D, Clynes R, de Bakker PI, Nöthen MM, Daly MJ, Christiano AM. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun 6:5966, 7/2015. e-Pub 1/2015. PMCID: PMC4451186.
6. Shiue LH, Couturier J, Lewis DE, Wei C, Ni X, Duvic M. The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4+Foxp3+CD25- T-cells in patients with leukemic cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 31(4):184-94, 7/2015. e-Pub 3/2015. PMCID: PMC4504772.
7. Alberti-Violetti S, Talpur R, Schlichte M, Sui D, Duvic M. Advanced-Stage Mycosis Fungoides and Sézary Syndrome: Survival and Response to Treatment. Clin Lymphoma Myeloma Leuk 15(6):e105-12, 6/2015. e-Pub 3/2015. PMID: 25817937.
8. Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of sweet syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(6):358-63, 6/2015. e-Pub 12/2014. PMCID: PMC4457594.
9. Litvinov IV, Tetzlaff MT, Rahme E, Habel Y, Risser DR, Gangar P, Jennings MA, Pehr K, Prieto VG, Sasseville D, Duvic M. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer 121(12):1993-2003, 6/2015. e-Pub 2/2015. PMCID: PMC4457714.
10. Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune--an anti-CD3ε recombinant immunotoxin induces durable remissions in cutaneous T cell lymphoma patients. Haematologica 100(6):794-800, 6/2015. e-Pub 3/2015. PMCID: PMC4450625.
11. Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. e-Pub 5/2015. PMID: 25791237.
12. Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M. Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. Clin Lymphoma Myeloma Leuk 15(5):e83-93, 5/2015. e-Pub 10/2014. PMID: 25458083.
13. de la Garza Bravo MM, Patel KP, Loghavi S, Curry JL, Torres Cabala CA, Cason RC, Gangar P, Prieto VG, Medeiros LJ, Duvic M, Tetzlaff MT. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol 46(4):558-69, 4/2015. e-Pub 12/2014. PMID: 25666664.
14. Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 168(6):811-9, 3/2015. e-Pub 11/2014. PMID: 25404094.
15. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 125(12):1883-9, 3/2015. e-Pub 1/2015. PMCID: PMC4375715.
16. Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Gangar P, Duvic M, Kim YH. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 72(2):286-92, 2/2015. e-Pub 12/2014. PMID: 25476993.
17. Herrmann JL, Syklawer E, Tarrillion M, Duvic M, Hughey LC. Concomitant Mycosis Fungoides and Vitiligo: How Mycosis Fungoides May Contribute to Melanocyte Destruction. Dermatology. e-Pub 1/2015. PMID: 25634551.
18. Ni X, Jorgensen JL, Goswami M, Challagundla P, Decker WK, Kim YH, Duvic M. Reduction of Regulatory T cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome. Clin Cancer Res 21(2):274-85, 1/2015. e-Pub 11/2014. PMID: 25376389.
19. Kash N, Vin H, Danialan R, Prieto VG, Duvic M. Stenotrophomonas maltophilia with histopathological features mimicking cutaneous gamma/delta T-cell lymphoma. Int J Infect Dis 30C:7-9, 1/2015. e-Pub 11/2014. PMID: 25462188.
20. Boulos S, Vaid R, Aladily TN, Ivan DS, Talpur R, Duvic M. Clinical presentation, immunopathology, and treatment of juvenile onset mycosis fungoides: A case series of 34 patients. J Am Acad Dermatol 71(6):1117-26, 12/2014. e-Pub 9/2014. PMID: 25264240.
21. Vin H, Talpur R, Tetzlaff MT, Duvic M. T-Cell Receptor-γ in Gamma-Delta Phenotype Cutaneous T-Cell Lymphoma Can Be Accompanied by Atypical Expression of CD30, CD4, or TCRβF1 and an Indolent Clinical Course. Clin Lymphoma Myeloma Leuk 14(6):e195-200, 12/2014. e-Pub 6/2014. PMID: 25088535.
22. Talpur R, Cox KM, Hu M, Geddes ER, Parker MK, Yang BY, Armstrong PA, Liu P, Duvic M. Vitamin D Deficiency in Mycosis Fungoides and Sézary Syndrome Patients Is Similar to Other Cancer Patients. Clin Lymphoma Myeloma Leuk 14(6):518-524, 12/2014. e-Pub 6/2014. PMID: 25442486.
23. Netchiporouk E, Litvinov IV, Moreau L, Gilbert M, Sasseville D, Duvic M. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle 13(21). e-Pub 11/2014. PMID: 25485578.
24. Kyvernitakis A, Duvic M, Mahale P, Torres HA. Interferon-Based Treatment for Patients with Mycosis Fungoides and Hepatitis C Virus Infection: A Case Series. Am J Clin Dermatol 15(5):451-6, 10/2014. e-Pub 6/2014. PMID: 24934807.
25. Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary Syndrome). Ann Oncol 25(9):1807-12, 9/2014. e-Pub 6/2014. PMID: 24948692.
26. Talpur R, Venkatarajan S, Duvic M. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin Pharmacol 7(5):1-7, 9/2014. e-Pub 7/2014. PMID: 25068889.
27. Bunata K, Jahan-Tigh RR, Curry J, Duvic M. A verrucous presentation of mycosis fungoides. Dermatol Online J 20(8), 8/2014. e-Pub 8/2014. PMID: 25148274.
28. Talpur R, Thompson A, Gangar P, Duvic M. Pralatrexate alone or in combination with Bexarotene: Long term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14(4):297-304, 8/2014. e-Pub 2/2014. PMID: 24589156.
29. Rangwala S, Duvic M. Antinuclear antibody seropositivity in men with cutaneous B-cell lymphoma of the scalp. Skinmed 12(4):244-8, Jul-Aug, 7/2014. PMID: 25335355.
30. Curry JL, Tetzlaff MT, Nicholson K, Duvic M, Kim KB, Tsai KY, Hwu WJ, Hong DS, Prieto VG, Torres-Cabala CA. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol 36(7):557-61, 7/2014. PMID: 24950418.
31. Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. e-Pub 6/2014. PMID: 24977319.
32. Applebaum DS, Daulat S, Duvic M. Multiple skin-colored papules with diffuse sclerosis. JAMA Dermatol. e-Pub 6/2014. PMID: 24919716.
33. Gera S, Dekmezian MS, Duvic M, Tschen JA, Vega F, Cho-Vega JH. Blastic plasmacytoid dendritic cell neoplasm: Evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement. Am J Dermatopathol 36(3):244-51, 3/2014. e-Pub 11/2013. PMID: 24247574.
34. Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG. Dermatologic toxicities to targeted cancer therapy: Shared clinical and histologic adverse skin reactions. Int J Dermatol 53(3):376-84, 3/2014. e-Pub 7/2013. PMID: 23879247.
35. Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase II trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood 123(8):1159-66, 2/2014. e-Pub 12/2013. PMID: 24335103.
36. Venkatarajan S, Duvic M. Sezary syndrome: an overview of current and future treatment options. Expert Opinion on Orphan Drugs 2(9). e-Pub 2/2014.
37. Dreno B, Urosevic-Maiwald M, Kim Y, Guitart J, Duvic M, Dereure O, Khammari A, Knol AC, Derbij A, Lusky M, Didillon I, Santoni AM, Acres B, Bataille V, Chenard MP, Bleuzen P, Limacher JM, Dummer R. TG1042 (Adenovirus-interferon-γ) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial. PLoS One 9(2):e83670, 2/2014. e-Pub 2/2014. PMCID: PMC3933342.
38. McQuitty E, Curry JL, Tetzlaff MT, Prieto VG, Duvic M, Torres-Cabala C. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis. J Cutan Pathol 41(2):88-100, 2/2014. e-Pub 10/2013. PMID: 24118002.
39. Straus DJ, Duvic M, Horwitz SM, Hymes K, Goy A, Hernandez-Ilizaliturri FJ, Feldman T, Wegner B, Myskowski PL. Final Results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol 25(1):206-10, 1/2014. e-Pub 11/2013. PMID: 24285015.
40. Aung PP, Climent F, Muzzafar T, Curry JL, Patel KP, Servitje O, Prieto VG, Duvic M, Jaffe ES, Torres-Cabala CA. Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol 41(1):51-7, 1/2014. e-Pub 11/2013. PMID: 24151865.
41. Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther 13(MCT-13-0561R):221-9, 1/2014. e-Pub 10/2013. PMCID: PMC4366425.

Book Chapters

1. Pozadzides J, Duvic M, Pro B. Chapter 9: T-cell lymphomas. In: The MD Anderson Manual of Medical Oncology, 3rd Ed, 3rd. Ed(s) Kantarjian HM, Wolff RA, Koller CA. McGraw-Hill, 2014.
2. Duvic M. Cutaneous T-cell lymphomas: Mycosis fungoides and Sezary syndrome. In: Lymphoma: Diagnosis and Treatment. Ed(s) Younes A, Coiffier B. Springer: New York, 287-329, 2013. ISBN: 978-1-62703-407-4.

Books (edited and written)

1. Vahquist A, Duvic M. Ed(s) Taylor & Frances. Retinoids and Carotenoids in Dermatology. Taylor & Frances, 2007.
2. Werth VP, Duvic M. Dermatologic Clinics on Medical Dermatology. WB Saunders, Inc., 2001.

Last updated: 8/25/2015